Traders Purchase Large Volume of Disc Medicine Put Options (NASDAQ:IRON)

Disc Medicine, Inc. (NASDAQ:IRON) was the recipient of some unusual options trading on Monday. Stock investors bought 5,395 put options on the company. This is an increase of 405% compared to the average volume of 1,068 put options.

Wall Street Analysts Forecast Growth

IRON has been the subject of a number of recent research reports. Cantor Fitzgerald boosted their price objective on shares of Disc Medicine from $125.00 to $170.00 and gave the company an “overweight” rating in a report on Monday. Wedbush reaffirmed an “outperform” rating and set a $100.00 target price on shares of Disc Medicine in a report on Thursday, September 10th. Morgan Stanley reiterated an “overweight” rating and issued a $90.00 price target on shares of Disc Medicine in a research note on Monday, August 17th. HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of Disc Medicine in a research report on Thursday, September 10th. Finally, Wall Street Zen lowered Disc Medicine from a “hold” rating to a “sell” rating in a research note on Saturday. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $110.40.

Disc Medicine Price Performance

Shares of IRON stock traded up $23.06 during trading hours on Monday, reaching $79.90. The company’s stock had a trading volume of 4,133,007 shares, compared to its average volume of 589,621. Disc Medicine has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The firm’s 50 day simple moving average is $71.55 and its 200-day simple moving average is $71.18. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $306.40 million, a price-to-earnings ratio of -12.01 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. Sell-side analysts forecast that Disc Medicine will post -6.61 earnings per share for the current year.

Insider Transactions at Disc Medicine

In other news, CEO John Quisel sold 33,000 shares of Disc Medicine stock in a transaction on Monday, August 17th. The stock was sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the completion of the sale, the chief executive officer owned 226,064 shares of the company’s stock, valued at approximately $17,892,965.60. This trade represents a 12.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jonathan Yu sold 8,796 shares of Disc Medicine stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total value of $731,123.52. Following the sale, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $4,515,410.88. This represents a 13.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 131,221 shares of company stock worth $10,239,760 over the last quarter. 3.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IRON. State of Wyoming bought a new stake in shares of Disc Medicine during the 2nd quarter valued at approximately $25,000. Allworth Financial LP acquired a new position in Disc Medicine during the 2nd quarter worth approximately $46,000. Nykredit A S acquired a new position in Disc Medicine during the 2nd quarter worth approximately $103,000. Quantbot Technologies LP bought a new position in Disc Medicine in the 2nd quarter valued at approximately $153,000. Finally, Seven Fleet Capital Management LP bought a new position in Disc Medicine in the 1st quarter valued at approximately $207,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine News Summary

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Bitopertin met the primary objective and all key goals in the Phase 3 APOLLO trial, strengthening the case that the drug could become a potential disease-modifying treatment for EPP. Disc Medicine’s rare disease drug succeeds in late-stage trial
• Positive Sentiment: Disc Medicine said it plans to resubmit bitopertin to the U.S. Food and Drug Administration, creating a significant regulatory catalyst following the successful trial. Disc Medicine’s Bitopertin Meets All Phase 3 Goals; FDA Resubmission Planned
• Positive Sentiment: The late-stage result removes a major clinical risk for IRON and drove a sharp rally as investors reassessed the commercial potential of the Roche-originated drug. Disc Medicine surges on late-stage trial win for lead asset developed with Roche
• Positive Sentiment: Bitopertin could address substantial unmet need because no disease-modifying therapy for EPP is currently approved, although the product remains investigational. Disc Medicine Says Metabolic Disorder Drug Meets Main Goal in Phase 3 Trial
• Neutral Sentiment: Disc Medicine scheduled an investor webcast to discuss the APOLLO topline data, giving investors additional details on efficacy, safety and the planned FDA filing. Disc Medicine to Host Corporate Webcast
• Negative Sentiment: Risks remain around FDA review, potential approval timing, commercialization costs and the company’s reliance on bitopertin as its primary value driver.
• Negative Sentiment: Recent reports questioned IRON’s valuation relative to book value, while disclosed insider activity showed selling and no purchases over the cited six-month period, which may weigh on sentiment. Disc Medicine Stock Still Looks Pricey As Book Value Lags Expectations

About Disc Medicine

Disc Medicine, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s research centers on disorders involving the production of red blood cells, iron metabolism and heme biology, areas that can contribute to anemia and other blood-related complications.

Disc Medicine’s lead product candidate is bitopertin, an oral small-molecule therapy designed to modulate glycine transporter 1 and influence heme production. The company is evaluating bitopertin in conditions including erythropoietic protoporphyria, a rare disorder associated with painful light sensitivity, as well as polycythemia vera and other hematologic diseases.

The company is also developing additional therapies intended to regulate iron availability and address anemia associated with chronic or hematologic conditions.